Progesterone in conjunction with estradiol has neuroprotective effects in an animal model of neurodegeneration

Pharmacology Biochemistry and Behavior

Volumn 64, Issue 4, 1999, Pages 777-785

  Vongher, Jill M ^a   Frye, Cheryl A ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

ChAT; Estradiol; Neur osteroid; Neurodegeneration; Neuroprotection; Nongenomic; Progesterone

Indexed keywords

COLCHICINE; ESTRADIOL; PROGESTERONE; STEROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIPPOCAMPUS; HORMONE ACTION; MAZE TEST; MEMORY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CHOLINE O-ACETYLTRANSFERASE; COLCHICINE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MAZE LEARNING; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PROGESTERONE; RATS; RATS, LONG-EVANS;

ANIMALIA;

EID: 0032712609     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(99)00140-9     Document Type: Article

References (71)

1. Alkayed N.J., Harukuni I., Kimes A.S., London E.D., Traysman R.J., Hum P.E. Gender-linked brain injury in experimental stroke. Stroke. 29:1997;159-166.
2. Ayres S., Tang M., Subbiah M.T.R. Estradiol-17-β as an antioxidant. Some distinct features when compared with common fat-soluble antioxidants J. Lab. Clin. Med. 128:1996;367-375.
3. Barret-Conner E., Bush T.L. Estrogen and coronary heart disease in women. JAMA. 265:1991;1861-1867.
4. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-417.
5. Berman K., Schmidt P., Rubinow D., Danaceau M., Van Horn J., Esposito G., Ostrem J., Weinberger D. Modulation of cognition-specific cortical activity by gonadal steroids. A positron-emission tomography study in women Neurobiology. 94:1997;8836-8841.
6. Brandeis R., Brandys Y., Yehuda S. The use of the Morris Water Maze in the study of memory and learning. Int. J. Neurosci. 48:1989;29-69.
7. Brandi A.M., Joannidis S., Peillon F., Joubert M. Changes of prolactin response to dopamine during the rat estrous cycle. Neuroendocrinology. 51:1990;449-454.
8. Brenner D.E., Kukull W.A., Stergachis A., van Belle G., Bowen J.D., McCormick W.C., Teri L., Larson E.B. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease. A population-based case-control study Am. J. Epidemiol. 140:1994;262-267.
9. Cramer D.W., Knapp R.C. Review of epidemiological studies of endometrial cancer and exogenous estrogen. Obstet. Gynecol. 54:1979;521-526.
10. Daniel J.M., Fader A.J., Spencer A.L., Dohanich G.P. Estrogen enhances performance of female rats during acquisition of a radial arm maze. Horm. Behav. 32:1997;217-225.
11. Ditkoff E.C., Crary W.G., Cristo M., Lobo R.A. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet. Gynecol. 78:1991;991-995.
12. Dohanich G.P., Fader A.J., Javorsky D.J. Estrogen and estrogen/progesterone treatments counteract the effect of scopolamine on reinforced T-Maze alteration in female rats. Behav. Neurosci. 108:1994;988-992.
13. Evans, D. A.: Descriptive epidemiology of Alzheimer's Disease. In: Khachaturian, Z. S.; Radebough, T. S., eds. Alzheimer's disease: Cause(s), diagnosis, treatment, and care, New York: CRC Press; 51-59; 1996.
14. Fader A.J., Hendricson A.W., Dohanich G.P. Estrogen improves performance of reinforced T-maze alternation and prevents the amnestic effects of scopolamine administered systemically or intrahippocampally. Neurobiol. Learn. Mem. 69:1998;225-240.
15. Fillit H., Weinreb H., Cholst I., Luine V., McEwen B., Amador R., Zabriskie J. Observations in a preliminary open trial estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology. 11:1986;337-345.
16. Fratiglioni L., Viitanen M., von Strauss E., Tontodonati V., Herlitz A., Winblad B. Very old women at highest risk of dementia and Alzheimer's disease. Neurology. 48:1997;132-138.
17. Fritts M.E., Roof R.L. Pregnanalone may mediate neuroprotective effects of progesterone after brain injury. Soc. Neurosci. Abstr. 27:1997;268.
18. Frye C.A. Estrus-associated decrements in a water maze task are limited to acquisition. Physiol. Behav. 57:1995;5-14.
19. Frye C.A., Bayon L.E. Seizure activity is increased in endocrine states characterized by decline in endogenous levels of the neurosteroid 3α,5α-THP. Neuroendocrinology. 68:1998;272-280.
20. Frye C.A., McCormick C.M., Coopersmith C., Erskine M.S. Effects of paced and non-paced mating stimulation on plasma progesterone, 3α-diol and corticosterone. Psychoneuroendocrinology. 21:1996;431-439.
21. Frye, C. A.; Scalise, T. J.: Anti-seizure effects of P and 3α,5α-THP in kainic acid and perforant pathway models of epilepsy. Psychoneuroendocrinology (in revision).
22. Frye C.A., Scalise T.J., Bayon L.E. Finasteride blocks the reduction in ictal activity produced by exogenous estrous cyclicity. J. Neuroendocrinol. 10:1998;291-296.
23. Gibbs R.B. Fluctuations in relative levels of choline acetyltransferase mRNA in different regions of the rat basal forebrain across the estrous cycle. Effects of estrogen and progesterone J. Neurosci. 16:1996;1049-1055.
24. Gibbs R.B. Effects of estrogen on basal forebrain cholinergic neurons vary as a function of dose and duration of treatment. Brain Res. 757:1997;10-16.
25. Gibbs R.B., Aggarwal P. Estrogen and basal forebrain cholinergic neurons. Implications for brain aging and Alzheimer's disease-related cognitive decline Horm. Behav. 34:1998;98-111.
26. Gibbs R.B., Hashash A., Johnson D.A. Effects of estrogen on potassium-stimulated acetylcholine release in the hippocampus and overlying cortex of adult rats. Brain Res. 749:1997;143-146.
27. Gibbs R.B., Pfaff D.W. Effects of estrogen and fimbria/fornix transection on p75(NGFR) and ChAT expression in the medial septum and diagonal band of Broca. Exp. Neurol. 116:1992;23-39.
28. Gibbs R.B., Wu D., Hersh L.B., Pfaff D.W. Effects of estrogen replacement on the relative levels of choline acetyltransferase, trkA, and nerve growth factor messenger RNAs in the basal forebrain and hippocampal formation of adult rats. Exp. Neurol. 129:1994;70-80.
29. Gilman S. Alzheimer's disease. Perspect. Biol. Med. 40:1997;230-245.
30. Goldschmidt R.B., Steward O. Neurotoxic effects of colchicine. Differential susceptibility of CNS neuronal populations Neuroscience. 7:1982;695-714.
31. Goodman R.L. A quantitative analysis of the physiological role of estradiol and progesterone in the control of tonic and surge secretion of LH in the rat. Endocrinology. 102:1978;142-150.
32. Gridley K.E., Green P.S., Simpkins J.W. Low concentrations of estradiol reduce beta-amyloid 925-350-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res. 778:1997;158-165.
33. Henderson V.W., Paganini-Hill A., Emanuel C.K., Dunn M.E., Buckwalter J.G. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects Arch. Neurol. 51:1994;896-900.
34. Honjo H., Ogino Y., Naitoh K., Urabe M., Kitawaki J., Yasuda J., Yamamoto T., Ishihara S., Okada H., Yonezawa T. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J. Steroid Biochem. 34:1989;521-525.
35. Honjo H., Tanaka K., Kashiwagi T., Urabe M., Okada H., Hayashi M., Hayashi K. Senile dementia-Alzheimer's type and estrogen. Horm. Metab. Res. 27:1995;204-207.
36. Ishimaru H., Takahashi A., Ikarashi Y., Maruyama Y. Immunohistochemical and neurochemical studies on hippocampal cholinergic neurons after ischemia. Neuroreport. 6:1995;557-560.
37. Iswari S., Colas A.E., Karavolas H.J. Binding of 5α-dihydroprogesterone and other progestins to female rat anterior pituitary nuclear extracts. Steroids. 47:1986;189-203.
38. Kasa P., Rakonczay Z., Gulya K. The cholinergic system in Alzheimer's disease. Prog. Neurobiol. 52:1997;511-535.
39. Ke L., Lukas R.J. Effects of steroid exposure on ligand binding and functional activities of diverse nicotinic acetylcholine receptor subtypes. J. Neurochem. 67:1996;1100-1112.
40. Kokate T.G., Cohen A.L., Karp E., Rogawski M.A. Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice. Neuropharmacology. 35:1996;1049-1056.
41. Konen J.A., Seymore P.M., Fritts M.E., Powell R.A., Stein D.G., Roof R.L. Delayed treatment with progesterone is effective at reducing edema, delayed treatment with methylprednisolone is not. Soc. Neurosci. Abstr. 27:1997;268.
42. Kuller L.H. Hormone replacement therapy and its potential relationship to dementia. J. Am. Geriatr. Soc. 44:1996;878-880.
43. Longcope, C.: Hormone dynamics at the menopause. Ann. NY Acad. Sci. 592;21-30; 1990.
44. Luine V.N. estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp. Neurol. 89:1985;484-490.
45. Luine V., Hearns M. Relationship of gonadal hormone administration sex, reproductive status and age to monoamine oxidase activity within the hypothalamus. J. Neuroendocrinol. 2:1990;423-428.
46. Luine V., McEwen B. Sex differences in cholinergic enzymes of diagonal band nuclei in the rat preoptic area. Neuroendocrinology. 36:1983;475-482.
47. Luine V., Park D., Joh T., Reis D., McEwen B. Immunochemical demonstration of increased choline acetyltransferase concentration in rat preoptic area after estradiol administration. Brain Res. 191:1980;273-277.
48. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 232:1986;1004-1007.
49. Matzkin H., Chen J., Lewyshon O., Ayalon D., Braf Z. Effects of long term treatment with finasteride (MK-906), a 5-α reductase inhibitor, on circulating LH, FSH, prolactin, and estradiol. Horm. Metab. Res. 24:1992;498-499.
50. McEwen B.S. Possible mechanisms for atrophy of the human hippocampus. Mol. Psychiatry. 2:1997;255-262.
51. Morley B.J., Rodriguez-Sierra J.F., Clough R.W. Increase in hypothalamic nicotinic acetylcholine receptors in prepuberal female rats administered estrogen. Brain Res. 278:1983;262-265.
52. Mundy W.R., Tilson H.A. Neurotoxic effects of colchicine. Neurotoxicology. 11:1990;539-548.
53. Nakagawa Y., Nakamura S., Kase Y., Noguchi T., Ishihara T. Colchicine lesions in the rat hippocampus mimic the alterations of several markers in Alzheimer's disease. Brain Res. 408:1987;57-64.
54. Ohkura T., Isse K., Akazawa K., Hamamoto M., Yaoi Y., Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type. 7 case reports Dementia. 6:1995;99-107.
55. Ohkura T., Isse K., Azakawa K., Hamamoto M., Yaoi Y., Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocrinol. Jpn. 41:1994;361-371.
56. Paganini-Hill A. Oestrogen replacement therapy and Alzheimer's disease. Br. J. Obstet. Gynaecol. 103:1996;80-86.
57. Payami H., Montee K., Grimslid H., Shattuc S., Kaye J. Increased risk of familial late-onset Alzheimer's disease in women. Neurology. 46:1996;126-129.
58. Perisic M., Cuenod M. Synaptic transmission depressed by colchicine blockade of axophasmic flow. Science. 175:1972;1140-1141.
59. Purdy R.H., Moore P.H., Narasimha Roa P., Hagino N., Yamaguchi T., Schmidt P., Rubinow D.R., Morrow A.L., Paul S.M. Radioimmunoassay of 3α-hydroxy-5α-pregnan-20-one in rat and human plasma. Steroids. 55:1990;290-296.
60. Rodbard, D.; Hutt, D. M.: Statistical analysis of radioimmunoassay and immunoradiometric assays: A generalized, weighted iterative, least squares method for logistic curve fitting. In: International Atomic Energy Agency. Symposium on Radioimmunoassay and related procedures in medicine. New York: Uniput; 1974.
61. Roof R.L., Duvdevani R., Stein D.G. Gender influences outcome of brain injury. Progesterone plays a protective role Brain Res. 607:1993;333-336.
62. Ryan J.P. Wandering in Alzheimer's disease. Clinical and neurobiological perspectives Spear N.E., Spear L.P., Woodruff M.L. Neurobehavioral plasticity. Learning, development, and response to brain insults:1995;Lawrence Erlbaum Associates, Hillsdale, NJ.
63. Schneider L.S., Farlow M.R., Henderson V.W., Pogoda J.M. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology. 46:1996;1580-1584.
64. Schneider L.S., Farlow M.R., Pogoda J.M. Potential role for estrogen replacement in the treatment of Alzheimer's dementia. Am. J. Medicine. 1903:1997;46A-50S.
65. Singh M., Meyer E.M., Millard W.J., Simpkins J.W. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res. 644:1994;305-312.
66. Sutherland R.J., Rudy J.W. Place learning in the Morris place navigation task is impaired by damage to the hippocampal formation even if the temporal demands are reduced. Psychobiology. 16:1988;157-163.
67. Tang M.-X., Jacobs D., Stern Y., Marder K., Schofield P., Gurland B., Andrews H., Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 348:1996;429-432.
68. Wenger N.K., Speroff L., Packard B. Cardiovascular health and disease in women. N. Engl. J. Med. 329:1993;247-256.
69. Yu Z.F., Cheng G.J., Hu B.R. Mechanism of colchicine impairment on learning and memory, and protective effect of CGP36742 in mice. Brain Res. 750:1997;53-58.
70. Zhang M., Katzman R., Salmon D., Jin H., Cai G., Wang Z., Qu G., Grant I., Yu E., Levy P., Klauber M.R., Liu W.T. The prevalence of dementia and Alzheimer's disease in Shanghai, China. Impact of age, gender, and education Ann. Neurol. 27:1990;428-437.
71. Zumoff B. Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy. Proc. Soc. Exp. Biol. Med. 217:1998;30-37.